Viral envelope fails to deliver?

Dani P. Bolognesi and Thomas J. Matthews
Additional contact information
Dani P. Bolognesi: Duke University Medical Center
Thomas J. Matthews: Duke University Medical Center

Nature, 1998, vol. 391, issue 6668, 638-639

Abstract: Clinical trials of vaccines against the human immunodeficiency virus are underway, but initial results do not seem promising — at least for one type of vaccine. By injecting patients with a recombinant form of a viral envelope protein, gp120, the idea was to induce an antibody response that could fight subsequent infection with the virus. But in a trial of 18 people, all became infected with HIV-1 and, at the level of the immune system, those who had received the vaccine did not seem to deal with the infection any differently than unvaccinated patients.

Date: 1998
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/35504 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:391:y:1998:i:6668:d:10.1038_35504

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/35504

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().